Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877072 | 0.90 | TRPV1 (0.42) | TRPV1MTORPIK3CAPIK3CDPIK3CB | |
| SCHEMBL3880570 | 0.89 | KDM4E (0.48) | PDE4DMTORPIK3CAPIK3CDPIK3CB | |
| SCHEMBL3879649 | 0.82 | TRPV1 (0.50) | TRPV1MTORPIK3CA | |
| SCHEMBL3880037 | 0.82 | TRPV1 (0.50) | TRPV1MTORPIK3CA | |
| SCHEMBL3879359 | 0.79 | PDE4D (0.46) | TRPV1PDE4DMTORPIK3CAPIK3CD | |
| SCHEMBL13761529 | 0.79 | PDE4D (0.46) | TRPV1PDE4DMTORPIK3CAPIK3CD | |
| SCHEMBL3877894 | 0.78 | HSD11B1 (0.47) | TRPV1MTORPIK3CAPIK3CDPIK3CB | |
| SCHEMBL3881506 | 0.78 | TRPV1 (0.45) | TRPV1MTORPIK3CA | |
| SCHEMBL3877163 | 0.76 | TRPV1 (0.49) | TRPV1MTORPIK3CAKDM4EL3MBTL1 | |
| SCHEMBL4029494 | 0.75 | TRPV1 (0.48) | TRPV1PIK3CAPIK3CDLMNAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | TRPV1 244/4885PDE4D 695/4885MTOR 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.